Aptamer Group PLC, together with its subsidiaries, provides synthetic binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, the United States, and internationally. The company offers Optimer, a platform that enables the discovery and development of optimized DNA and RNA aptamers, which can bind to target molecules. Its platform is used in research reagent and analytical, bioprocessing, diagnostic, cosmetic and consumer health, and therapeutic applications. The company serves pharmaceutical, diagnostic, and bioprocessing companies. It has collaborations with Unilever. Aptamer Group PLC was founded in 2008 and is headquartered in York, the United Kingdom.…
Aptamer Group Plc (LSE:APTA): The Next Catalyst Could Shape the Market Story for This Small-Cap Growth Stock
Aptamer Group (LON: APTA) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 34 employees.
The shares were at 0.2850 GBp on 20 November 2026, down 68.3% over 52 weeks. Its 52-week range is 0.2500 GBp to 1.150 GBp: the price is 75.2% below the high and 14.0% above the low.
Its market capitalisation is 9.88M GBP.
Aptamer Group reports return on equity of -175.4%, an operating margin of -181.2% and revenue up 30.2% year over year.
It holds more cash than debt, a net cash position of 4.19M GBP. Its Piotroski F-score is 6 out of 9, an average reading of its financial health.
No upcoming events tracked.